CSPG4 and melanoma: Freeman et al., using immunomagnetic enrichment and combination of MCAM, melanoma-associated chondroitin sulfate proteoglycan (MCSP), ABCB5 and CD271 markers, showed that significantly more patients harbored CMCs in comparison to healthy individuals.